NCT01124344

Safety and Pharmacology Study of BMS-866949

Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-866949 in Healthy Subjects

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 47 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 21 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to determine whether multiple doses.of BMS-886949 are safe and tolerable

Conditions

• Major Depression

Interventions

Type	Name	Description
DRUG	Placebo	Oral Solution, Oral, 0 mg, Once Daily, 14 days
DRUG	BMS-866949	Oral Solution, Oral, 3 mg, Once Daily, 14 days
DRUG	BMS-866949	Oral Solution, Oral, 10 mg, Once Daily, 14 days
DRUG	BMS-866949	Oral Solution, Oral, 30 mg, Once Daily, 14 days
DRUG	BMS-866949	Oral Solution, Oral, 45 mg, Once Daily, 14 days
DRUG	BMS-866949	Oral Solution, Oral, 60 mg, Once Daily, 14 days
DRUG	BMS-866949	Oral Solution, Oral, 90 mg, Once Daily, 14 days
DRUG	BMS-866949	Oral Solution, Oral, 3-60 mg, Once Daily, 14 days

Timeline

• Start date: 2010-05-01
• Primary completion: 2011-11-01
• Completion: 2011-11-01
• First posted: 2010-05-17
• Last updated: 2012-03-27

Locations

1 site across 1 country: Sweden